AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Cocrystal Pharma's CDI-988 Gets IRB Approval for Phase 1b Norovirus Study
ByAinvest
Thursday, Dec 18, 2025 8:09 am ET1min read
Cocrystal Pharma has received IRB approval from Emory University School of Medicine to initiate a Phase 1b human challenge study with CDI-988. The study aims to evaluate CDI-988 as both a preventive and treatment for norovirus infections. Screening of study subjects is underway, with enrollment expected to begin in Q1 2026. CDI-988 is the first oral broad-spectrum antiviral drug candidate for norovirus, with no approved treatments or vaccines currently available.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet